Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours

Core Viewpoint - Zelluna has published strong preclinical data for its lead candidate ZI-MA4-1, supporting the initiation of clinical trials planned for 2026 [1][3]. Group 1: Product Overview - ZI-MA4-1 is a novel cell therapy that combines T cell receptors (TCRs) for precise targeting of solid tumors with the broad cancer-killing ability of Natural Killer (NK) cells [2][7]. - The therapy specifically targets MAGE-A4, a protein present in various solid cancers, including lung, ovarian, head and neck cancers, and sarcomas [2][7]. Group 2: Key Results - ZI-MA4-1 is manufactured in advance and stored frozen, allowing for on-demand patient administration, which facilitates multiple doses to sustain tumor response and broad patient access [2][9]. - The therapy has demonstrated effectiveness in killing cancer cells across multiple tumor types and remains active despite common escape mechanisms employed by tumors [5][12]. Group 3: Clinical Development Plans - Zelluna plans to submit its Clinical Trial Application (CTA) in late 2025, with the first patient data expected by mid-2026 [3][10]. - The company is well-positioned to start clinical trials in 2026, having completed preclinical data and locked the manufacturing process [3][10]. Group 4: Company Background - Zelluna is pioneering allogeneic off-the-shelf TCR-NK cell therapies for solid cancers, aiming to address the limitations of current cell therapies [4][11]. - The company is headquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway, and is listed on the Oslo Stock Exchange under the ticker ZLNA [4][11].